Clinical Trial Update: Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating faricimab for extended durability in neovascular age-related macular degeneration (nAMD) has completed with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Faricimab (faricimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascularization, Choroidal, Macular Degeneration, Age-Related | Phase 2 | Status: COMPLETED | Results posted: 2021-01-05